Can I Take GLP-1? Exploring the Benefits and Considerations of GLP-1 Agonists

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Whether you can take a GLP-1 receptor agonist is a clinical determination that belongs to a prescriber who can see your history — but the approved labels do state, in plain terms, who must not take them. Semaglutide and tirzepatide products are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a serious hypersensitivity reaction to the drug or its excipients. Everything else — the warnings, the interactions, the populations needing extra care — shapes a conversation rather than closing it. This article covers what that conversation should contain.

The Boxed Warning and the Absolute Contraindications

Both the Wegovy and Ozempic labels open with the same boxed warning. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether it causes thyroid C-cell tumors including medullary thyroid carcinoma in humans is unknown, because the human relevance of the rodent findings has not been determined. Tirzepatide products carry an equivalent warning.

From that flows the contraindication: these medications must not be used by patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The second contraindication is a prior serious hypersensitivity reaction — including anaphylaxis or angioedema — to the drug or any excipient. The labels also note that anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists and advise caution in patients with such a history, since it is unknown whether they will be predisposed to the same reaction.

The Warnings That Require a Real Discussion

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists; the labels direct discontinuation if pancreatitis is suspected and describe persistent or severe abdominal pain, sometimes radiating to the back, as the presenting symptom. Acute gallbladder disease is an established risk, and the labels note that substantial or rapid weight loss itself increases the risk of cholelithiasis — with incidence still higher in treated patients than in placebo groups even after accounting for degree of weight loss.

Hypoglycemia is largely a combination risk: these agents stimulate insulin secretion in a glucose-dependent manner, so the labeled concern is concomitant use with insulin or an insulin secretagogue such as a sulfonylurea. Acute kidney injury due to volume depletion has been reported postmarketing, mostly in patients who became dehydrated from nausea, vomiting or diarrhea. Severe gastrointestinal reactions were reported in 4.1% of Wegovy injection patients versus 0.9% on placebo, and the product is not recommended in patients with severe gastroparesis.

Three more warrant naming: diabetic retinopathy complications in patients with type 2 diabetes, where patients with a history of retinopathy should be monitored; increases in resting heart rate, with mean rises of 1 to 4 beats per minute in adult weight-reduction trials and instructions to discontinue if a sustained increase occurs; and rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation, which is why patients are told to inform providers about any planned surgery or procedure.

Populations That Need Extra Care

Pregnancy is a clear one. The Wegovy label states semaglutide may cause fetal harm, directs discontinuation when pregnancy is recognized for patients treated for cardiovascular risk reduction or weight reduction, and advises discontinuing at least two months before a planned pregnancy because of semaglutide's long half-life. Breastfeeding is not recommended during treatment with Wegovy tablets.

Type 1 diabetes is not a studied population — the Wegovy label states its use in patients with type 1 diabetes, or in combination with insulin, has not been evaluated. Pediatric use is indication-specific: Wegovy injection carries a weight-reduction indication for patients aged 12 and older with obesity, but Wegovy tablets do not, and safety has not been established in pediatric patients for several other uses. Anyone already taking another GLP-1 receptor agonist falls under an explicit limitation of use, since concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.

Drug Interactions Are Not Uniform Across Labels

This is a detail that gets flattened in most summaries. Because these drugs delay gastric emptying, they can influence the absorption of concomitantly administered oral medications — but the two labels handle it differently. Ozempic's drug interaction section advises using caution with oral medications. Wegovy's goes further, directing that increased clinical or laboratory monitoring be considered when used concomitantly with other oral medications that have a narrow therapeutic index or that require clinical monitoring.

If you take a narrow-therapeutic-index medication — the class includes drugs such as levothyroxine, warfarin and certain antiepileptics — that difference is worth raising explicitly with your prescriber and your pharmacist, along with your full medication list rather than a summary of it.

What the Benefits Look Like in Trials

The efficacy case is strong where it has been tested. In the Zepbound label's Study 1, a 72-week trial in 2,539 adults, mean weight change was −15.0%, −19.5% and −20.9% across the three dosages versus −3.1% with placebo. In SELECT, 17,604 adults with established cardiovascular disease and a BMI of 27 or greater but without diabetes were randomized to semaglutide 2.4 mg or placebo; the primary cardiovascular endpoint occurred in 6.5% versus 8.0%, a hazard ratio of 0.80.

And in STEP-HFpEF, 529 patients with heart failure with preserved ejection fraction and a BMI of 30 or higher saw a 16.6-point improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score versus 8.7 on placebo over 52 weeks. Those are the kinds of outcomes that make this class worth considering seriously — and they were all achieved alongside diet and activity intervention, not instead of it.

How to Prepare for the Conversation

Bring a complete medication and supplement list, your personal and family history of thyroid cancer and endocrine syndromes, any history of pancreatitis, gallbladder disease, kidney disease, severe gastrointestinal disease or diabetic retinopathy, your pregnancy status and plans, and an honest account of previous attempts and what happened. Bring your questions about what happens if you stop, because the withdrawal trials show weight regain is the pattern.

What you should not bring is a decision already made by a website. The value of a prescriber is not in granting permission at the start; it is in the follow-up — assessing tolerability, watching heart rate and blood pressure, checking glycemic effects if you have diabetes, and deciding together whether to continue.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Who cannot take a GLP-1 receptor agonist at all?

The approved labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, which follows from a boxed warning based on dose-dependent thyroid C-cell tumors observed in rodents at clinically relevant exposures. They are also contraindicated in anyone with a prior serious hypersensitivity reaction, including anaphylaxis or angioedema, to the drug or any excipient in the product.

Can I take a GLP-1 medication if I am pregnant or planning to be?

The Wegovy label states semaglutide may cause fetal harm and directs discontinuation when pregnancy is recognized for patients treated for cardiovascular risk reduction or weight reduction. It further advises discontinuing at least two months before a planned pregnancy because of semaglutide's long half-life of approximately one week. Breastfeeding is not recommended during treatment with Wegovy tablets. Discuss timing with your prescriber well in advance.

Do GLP-1 medications interact with my other prescriptions?

They can, because delayed gastric emptying may influence the absorption of oral medications, and the labels differ. Ozempic's drug interaction section advises using caution with oral medications. Wegovy's directs considering increased clinical or laboratory monitoring when used with oral drugs that have a narrow therapeutic index or require monitoring. Give your prescriber and pharmacist your complete medication and supplement list, not a summary.

What if I already take another GLP-1 medication?

Combining is not supported by the labeling. Wegovy states a limitation of use against concomitant use with other semaglutide-containing products or any other GLP-1 receptor agonist, and Zepbound states that coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. Tell your prescriber about any current or recent agent in this class before a new prescription is considered.

What symptoms mean I should contact a clinician promptly?

Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, may indicate pancreatitis and the labels direct discontinuation if it is suspected. Swelling of the face, lips, tongue or throat, or difficulty breathing, may indicate angioedema and needs emergency care. Also report sustained increases in resting heart rate, symptoms of gallbladder disease, and any dehydration from prolonged vomiting or diarrhea.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.